Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 2/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.40 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.37 |
| ▸ | CHAT | P28329 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166530 | 0.93 | TSHR (0.41) | BCAT2CASP1TTRHNF4ADAPK1 | |
| SCHEMBL392931 | 0.93 | TSHR (0.41) | BCAT2CASP1TTRHNF4ADAPK1 | |
| Hydrochloric Acid SCHEMBL11760140 | 0.91 | PTGS2 (0.40) | BCAT2SLC9A1CASP1TTRHNF4A | |
| Phthalic Acid SCHEMBL8745684 | 0.87 | HNF4A (0.53) | BCAT2HNF4ACYP2D6FABP4TSHR | |
| SCHEMBL27690669 | 0.86 | STAT3 (0.44) | BCAT2PTGS2CDK2 | |
| (Z)-1,2-Diphenylethene SCHEMBL28265888 | 0.83 | PTPN1 (0.44) | CASP1TTRCHATSNCACYP1A2 | |
| SCHEMBL21794264 | 0.83 | TSHR (0.46) | BCAT2SLC9A1FGFR1FGFR2FGFR4 | |
| Ether SCHEMBL2731657 | 0.81 | PTGS2 (0.37) | SLC9A1CASP1TTRCHATSNCA | |
| SCHEMBL460175 | 0.80 | HNF4A (0.38) | BCAT2CASP1TTRHNF4ADAPK1 | |
| SCHEMBL2731656 | 0.79 | CASP1 (0.37) | BCAT2CASP1TTRHNF4ACHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030181416-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | TRIDENT GROWTH FUND, LP | 2003-09-25 | — | — | US | claimed |
| EP-1718315-A4 | HIGH DOSE, SHORT INTERVAL USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF INFECTIONS | UNIV MONASH (AU) | 2008-08-13 | — | — | EP | disclosed |
| US-20080004236-A1 | High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections | COMPER WAYNE D | 2008-01-03 | — | — | US | disclosed |
| US-20070027109-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | MONASH UNIVERSITY | 2007-02-01 | — | — | US | disclosed |
| EP-1718315-A1 | HIGH DOSE, SHORT INTERVAL USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF INFECTIONS | Monash University (AU) | 2006-11-08 | — | — | EP | disclosed |
| US-20060084631-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | MONASH UNIVERSITY | 2006-04-20 | — | — | US | disclosed |
| EP-1062325-B1 | PURIFICATION OF VIRUS PREPARATIONS | CANTAB PHARMACEUTICALS RES LTD (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2006003521-A1 | HIGH DOSE, SHORT INTERVAL USE OF SULFATED POLYSACCHARIDES FOR THE TREATMENT OF INFECTIONS | MONASH UNIVERSITY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005004882-A1 | ANTIVIRAL CHARGED POLYMERS THAT EXHIBIT RESISTANCE TO LYSOSOMAL DEGRADATION DURING KIDNEY FILTRATION AND RENAL PASSAGE, COMPOSITIONS AND METHODS OF USE THEREOF | MONASH UNIVERSITY (AU) | 2005-01-20 | — | — | WO | disclosed |
| US-20050009782-A1 | Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof | TRIDENT GROWTH FUND, LP | 2005-01-13 | — | — | US | disclosed |
| US-20050004071-A1 | Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses | TRIDENT GROWTH FUND, LP | 2005-01-06 | — | — | US | disclosed |
| WO-2004093888-A1 | CHARGED POLYSACCHARIDES RESISTANT TO LYSOSOMAL DEGRADATION DURING KIDNEY FILTRATION AND RENAL PASSAGE AND THEIR USE TO TREAT OR PREVENT INFECTION BY CORONAVIRUSES | MONASH UNIVERSITY (AU) | 2004-11-04 | — | — | WO | disclosed |
| US-20040009953-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | TRIDENT GROWTH FUND, LP | 2004-01-15 | — | — | US | disclosed |
| US-20030181416-A1 | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof | TRIDENT GROWTH FUND, LP | 2003-09-25 | — | — | US | disclosed |
| US-6267967-B1 | Virus preparations and methods | CANTAB PHARMACEUTICALS RESEARCH LIMITED (GB) | 2001-07-31 | — | — | US | disclosed |
| EP-1062325-A2 | PURIFICATION OF VIRUS PREPARATIONS | CANTAB PHARMACEUTICALS RESEARCH LIMITED (GB) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045104-A2 | PURIFICATION OF VIRUS PREPARATIONS | CANTAB PHARMACEUTICALS RESEARCH LIMITED (GB) | 1999-09-10 | — | — | WO | disclosed |